Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
More news for Friday, Dec. 2
By
Kimberly Bonvissuto
Dec 02, 2022
Bill targets reform of CMS drug coverage authority in wake of aducanumab decision … FCC moves to improve affordable connectivity program for HUD residents … Partnership launches cybersecurity hub,...
Ultrasound tech could allow for ultrafast Alzheimer’s treatment, study finds
By
Aaron Dorman
Jan 09, 2024
Researchers have found a way to deliver Alzheimer’s drugs faster via focused ultrasound technology, a new study shows.
Lawmakers turn up heat on CMS to expand access to Alzheimer’s treatments
By
Kimberly Bonvissuto
Apr 28, 2023
Medicare needs to reconsider its national coverage decision on FDA-approved Alzheimer’s drug treatments, bipartisan members of the House told Centers for Medicare & Medicaid Services Administrator Chiquita...
A stumbling block on the way to an Alzheimer’s cure
By
Lois A. Bowers
Nov 14, 2022
In a new study, 56% of participants said they were not likely to take part in a trial of a dementia-prevention drug. Senior living may be able to play a role in decreasing that percentage.
Monoclonal antibodies provide small benefits in Alzheimer’s disease
Jan 26, 2024
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.